What Is ACE-031?
ACE-031 peptide is one of the more mechanistically distinctive compounds currently being explored in muscle growth peptide and bone density peptide research circles. It is a soluble form of the type IIB activin receptor (ACVR2B), studied for its potential regulatory interactions with muscle growth through its proposed ability to bind with and subsequently inactivate myostatin, a negative regulator of muscle growth that functions as a potent inhibitor of both skeletal muscle hypertrophy and hyperplasia in laboratory models.
What makes this muscle growth peptide particularly interesting from a research standpoint is its proposed ability to target multiple negative regulators of skeletal muscle growth simultaneously in laboratory settings. While myostatin is considered a primary negative regulator, other members of the transforming growth factor-β superfamily, including activin A and bone morphogenetic proteins, may also play roles in inhibiting muscle development in laboratory models. Research by Cadena et al. suggested that introducing a soluble form of the activin type IIB receptor may possibly increase muscle mass more effectively than a myostatin-specific neutralizing antibody in laboratory settings, with additional increases in muscle mass observed in myostatin-deficient laboratory models when soluble ActRIIB was introduced.
ACE-031 Peptide and Energy Metabolism Research
At the foundation of ACE-031 peptide research is its proposed interactions with muscle energy metabolism in laboratory models. Research by Relizani et al. suggested that myostatin may play a role in muscle energy metabolism in laboratory settings, with elevated myostatin levels potentially associated with excessive muscle fatigue in these models. In experimental settings where the natural form of ACE-031 was blocked in laboratory models, researchers reported a notable increase in serum lactate levels and severe metabolic damage to muscles, alongside a reduction in the number of blood vessels supplying muscle tissue in these experimental settings.
ACE-031 supplementation, by contrast, appeared to promote muscle growth in laboratory models by potentially inhibiting myostatin and enhancing the oxidative capacity of muscles. Researchers proposed this improvement in oxidative capacity may serve as a protective measure against fatigue and the detrimental consequences of free radical production in laboratory settings. Researchers noted that ActRIIB signaling appeared to regulate key determinants of muscle metabolism in laboratory models, including Pparβ, Pgc1α, and Pdk4, thereby potentially optimizing different components of muscle energy metabolism in these experimental settings.
ACE-031 Peptide and Muscle Strength Research
Building on its energy metabolism research profile, ACE-031 has also been studied for its proposed interactions with muscle force generation in laboratory models. Research by Béchir et al. suggested that ACE-031 exposure appeared to enhance the force-generating capacity of muscle tissue in laboratory settings, with researchers attributing this to the potential preservation of energy supply and a shift in muscle thermodynamics toward oxidative respiration in these models.
Researchers reported observations of significant enhancement in both maximum and total contractile force in laboratory models following ACE-031 exposure, with no discernible impact on overall muscle fatigue in these experimental settings. Further investigation suggested that ACE-031 may not induce significant alterations in ATP homeostasis or contractile efficiency in laboratory models, with researchers proposing the observed improvements in force-generating capacity may be attributable to mechanisms specifically involved in force production in these settings.
ACE-031 Peptide and Muscle Protection Research
ACE-031 has also been evaluated for its potential interactions with muscle mass preservation in laboratory research models. Research by Attie et al. in a placebo-controlled study suggested that ACE-031 may have induced increases in lean body mass and thigh muscle volume in laboratory models following a single introduction. Researchers noted a particularly interesting secondary observation in these laboratory settings: models receiving ACE-031 appeared to demonstrate improvement in serum biomarkers associated with both bone and fat metabolism, suggesting that while ACE-031’s primary association lies with muscle growth, it may exhibit broader metabolic interactions in these experimental settings.
ACE-031 Peptide and Muscle Wasting Research
One of the more clinically focused areas of ACE-031 muscle growth peptide research involves its proposed interactions with muscle wasting conditions in laboratory models. Research by Campbell et al. explored ACE-031 in laboratory models of Duchenne Muscular Dystrophy, a genetic disorder characterized by profound muscle loss in which dysfunctional dystrophin protein renders muscle cells weak and susceptible to damage in laboratory research contexts. Results indicated a trend toward maintaining muscle function in these laboratory models, alongside observations of increased lean body mass, improved bone mineral density, and reduced fat mass. Researchers proposed that myostatin inhibition represents a promising approach for studying DMD in laboratory settings, carefully framing all findings as preliminary observations.
Research by Morvan et al. further suggested that comprehensive muscle protection in laboratory conditions characterized by muscle wasting may require a multifaceted approach, potentially combining interventions that enhance muscle growth including growth hormone and IGF-1 with strategies that moderate muscle wasting such as ACE-031 in these experimental settings.
ACE-031 Peptide and Bone Density Research
One of the most distinctively documented areas of ACE-031 bone density peptide research involves its proposed interactions with bone mineral density in laboratory models, extending well beyond its primary muscle growth research profile. Research by Puolakkainen et al. in a mouse model of Duchenne Muscular Dystrophy suggested that ACE-031 exposure appeared to produce a significant increase in total body and muscle weight alongside improved bone mineral density in these laboratory settings. Researchers attributed this enhancement to a decrease in osteoclasts responsible for bone breakdown in these models, with strength testing indicating that improved mineralization may have resulted in enhanced biomechanics of the bones in laboratory settings.
Research by Bialek et al. comparing ACE-031 to a strict myostatin inhibitor in laboratory mouse models provided particularly compelling bone density peptide research observations. While both ACE-031 and the myostatin inhibitor appeared to increase muscle mass in these laboratory models, only ACE-031 appeared to improve bone density, with researchers reporting a substantial increase in femur density and vertebrae density in these experimental settings. Researchers proposed these findings strongly suggest that ACE-031 may interact with additional molecular targets beyond myostatin in laboratory models, potentially contributing to its distinct interactions with bone metabolism in these settings.
ACE-031 Peptide and Cancer Research
Rounding out this muscle growth and bone density peptide’s broad laboratory research profile, ACE-031 has also been explored for its potential interactions with cancer-related muscle wasting in laboratory cell culture models. Research suggested that ACE-031 may possibly inhibit the activation of the ERK1/2 pathway in muscle cells in laboratory settings, potentially preventing muscle fiber atrophy by impeding programmed cell death in these models. Researchers also proposed that ACE-031 may preserve mitochondrial function and potentially enhance muscle fiber energy efficiency in laboratory models, with these interactions considered particularly relevant in cancer research contexts where muscle wasting represents a significant area of laboratory investigation.
Researchers further proposed that myostatin inhibition in cancer laboratory research settings could potentially moderate insulin sensitivity, reduce fat accumulation, moderate inflammation, and possibly support bone strength in these experimental contexts. All cancer-related findings are presented as preliminary laboratory observations requiring substantial further investigation before any broader conclusions can be drawn.
References
- Cadena SM, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol. 2010;109(3):635–42.
- Relizani K, et al. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Mol Ther. 2014;22(8):1423–1433.
- Béchir N, et al. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo. FASEB J. 2016;30(10):3551–3562.
- Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416–23.
- Morvan F, et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc Natl Acad Sci. 2017;114(47):12448–12453.
- Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy. Muscle Nerve. 2017;55(4):458–464.
- Puolakkainen T, et al. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskelet Disord. 2017;18(1):20.
- Bialek P, et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone. 2014;60:162–71.
- Lokireddy S, et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J. 2012;446(1):23–36.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
